Savara Stock Forecast, Price & News

-0.11 (-6.08 %)
(As of 06/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume911,774 shs
Average Volume2.87 million shs
Market Capitalization$193.19 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

Savara logo

About Savara

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.68 out of 5 stars

Medical Sector

167th out of 2,105 stocks

Pharmaceutical Preparations Industry

75th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Savara (NASDAQ:SVRA) Frequently Asked Questions

Is Savara a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Savara stock.
View analyst ratings for Savara
or view top-rated stocks.

What stocks does MarketBeat like better than Savara?

Wall Street analysts have given Savara a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Savara wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Savara

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) released its earnings results on Thursday, May, 13th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.05.
View Savara's earnings history

How has Savara's stock been impacted by COVID-19 (Coronavirus)?

Savara's stock was trading at $2.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SVRA shares have decreased by 28.0% and is now trading at $1.70.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SVRA?

4 brokers have issued 1-year price objectives for Savara's shares. Their forecasts range from $3.00 to $7.00. On average, they expect Savara's share price to reach $4.67 in the next twelve months. This suggests a possible upside of 174.5% from the stock's current price.
View analysts' price targets for Savara
or view top-rated stocks among Wall Street analysts.

Who are Savara's key executives?

Savara's management team includes the following people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

Who are some of Savara's key competitors?

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by a number of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (24.15%), BlackRock Inc. (5.77%), Janus Henderson Group PLC (2.32%), Ikarian Capital LLC (1.72%), Geode Capital Management LLC (0.79%) and Millennium Management LLC (0.44%). Company insiders that own Savara stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken and Matthew Pauls.
View institutional ownership trends for Savara

Which institutional investors are selling Savara stock?

SVRA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Brown Advisory Inc., and Northern Trust Corp.
View insider buying and selling activity for Savara
or view top insider-selling stocks.

Which institutional investors are buying Savara stock?

SVRA stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Janus Henderson Group PLC, Ikarian Capital LLC, Millennium Management LLC, Russell Investments Group Ltd., Geode Capital Management LLC, Nuveen Asset Management LLC, and Cubist Systematic Strategies LLC. Company insiders that have bought Savara stock in the last two years include David A Ramsay, David L Lowrance, Joseph S Mccracken, and Matthew Pauls.
View insider buying and selling activity for Savara
or or view top insider-buying stocks.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $1.70.

How much money does Savara make?

Savara has a market capitalization of $193.19 million and generates $260,000.00 in revenue each year.

What is Savara's official website?

The official website for Savara is

Where are Savara's headquarters?

Savara is headquartered at 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.